US › Healthcare

In8bio Inc (INAB)

US · Healthcare · Biotechnology

$1.11-6.33%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.8M

EPS

$-0.25

EPS estimate

$-0.61

EPS came in at -0.25 against a street estimate of -0.61 — a beat of 59.0%.

Key statistics

Market cap

$12.1M

Forward P/E

0.0

P/B

0.60

Book value

$1.86

EPS (TTM)

$-1.62

52-week high

$2.73

52-week low

$0.88

50-day MA

$1.15

200-day MA

$1.54

Beta

0.30

Analyst view

Analysts rate In8bio Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $7.00.

Shareholding

Insiders

7.58%

Institutions

38.45%

Largest institutional holders

Fund	Stake
Alyeska Investment Group, L.P.	9.58%
Franklin Templeton Inc	9.28%
683 Capital Management LLC	7.35%
Stonepine Capital Management Llc	7.05%
Vanguard Capital Management, LLC	0.90%
BIOS CAPITAL MANAGEMENT, LP	0.82%
Geode Capital Management, LLC	0.74%
Citadel Advisors Llc	0.64%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for In8bio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.